 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2021, vol. 27, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2021271.3543
Published online: 22 January 2021
Original article
J of IMAB. 2021 Jan-Mar;27(1):3543-3548
RISK FACTORS IN PATIENTS WITH BISPHOSPHONATE - ASSOCIATED OSTEONECROSIS OF THE JAWS
Meri Hristamyan1
, Ralitsa Raycheva2, Petia Pechalova3, Veselka Hristamyan4, Yordanka Stoilova1,
1) Department of Epidemiology and DM, Faculty of Public Health, Medical University - Plovdiv, Bulgaria
2) Department of Social Medicine, Faculty of Public Health, Medical University - Plovdiv, Bulgaria
3) Department of Oral Surgery, Faculty of Dental Medicine, Medical University - Plovdiv, Bulgaria
4) Clinic of Maxillo-facial Surgery, UMHAT "St. George" - Plovdiv, Bulgaria.
ABSTRACT:
Purpose: To investigate patient diagnosed with BAONJ in order to identify the presence of risk factors.
Material/Methods: A prospective epidemiological study of 112 patients diagnosed with Bisphosphonate-associated Osteonecrosis of the jaw in 2016 and 2017 was conducted in the Clinic of maxillo-facial surgery of UMHAT "St. George", Plovdiv, Bulgaria, based on anamnesis, clinical examination, hospital documentation, and imaging studies. SPSS Statistics v.24 was used for statistical analysis, at a significance level p<0.05.
Results: Of the patients, 77.89% had a primary oncological diagnosis of breast or prostate cancer; the average duration of bisphosphonate therapy up to the time of the study is 4.5 years; the most common co-morbidities were hypertension (72.73%), anemia (40.00%) and diabetes (23.67%); 65.18% of patients smoke or are former smokers; the time till first oral complaints after initiation of BP treatment was usually 2 years (31.25%, n = 35) and 3 years (24.11%, n = 27) (p> 0.05).; the last dental manipulation before the onset of symptoms was tooth extraction (52.68%), followed by removable dentures (21.42%).
Conclusions: The investigation of identified in the literature risk factors with their occurrence in the studied population shows a correlation with the data of leading researchers.
Keywords: bisphosphonates, Osteonecrosis, risk factors, oncology, epidemiology,
- Download FULL TEXT /PDF 1500 KB/
Please cite this article as: Hristamyan M, Raycheva R, Pechalova P, Hristamyan V, Stoilova Y. Risk Factors in Patients with Bisphosphonate - Associated Osteonecrosis of the Jaws. J of IMAB. 2021 Jan-Mar;27(1):3543-3548. DOI: 10.5272/jimab.2021271.3543
Correspondence to: Dr Meri Hristamyan, PhD, Department of Epidemiology and DM, Faculty of Public Health, Medical University – Plovdiv; 15A, Vasil Aprilov Str., Plovdiv, Bulgaria; E-mail: mary_hr@abv.bg
REFERENCES:
1. Hristamyan MA. Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaws: Review of the Literature. ARC J Dent Sci. 2018; 3(1):6-10. [Crossref]
2. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosisofthejawincanceraftertreatmentwithbisphosphonates: incidence and risk factors. J Clin Oncol. 2005 Dec 1;23(34):8580-7. [PubMed]
3. Campisi G, Fedele S, Fusco V, Pizzo G, Di Fede O, Bedogni A. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014 Feb;10(2):257-75. [PubMed]
4. Rugani P, Walter C, Kirnbauer B, Acham S, Begus-Nahrman Y, Jakse N. Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma. Dent J (Basel). 2016 Sep 27;4(4):32. [PubMed]
5. Berenson JR, Stopeck AT. Medication-related Osteonecrosis of the jaw in patients with cancer. Up To Date. 2015. [Internet]
6. Marx RE. Risk factors for antiresorptive drug-related Osteonecrosis of the jaw. In: Antiresorptive Drug-Related Osteonecrosis of the Jaw (ARONJ) - A GuidetoResearch. 1st edition. Fleisher KE, Kontio R, Otto S. (Editors). Thieme. September 16, 2016. pp.39-44.
7. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A retrospective study evaluating frequency and risk factors of Osteonecrosis of the jaw in 576 cancer patients receiving in intravenous bisphosphonates. Am J ClinOncol. 2012 Aug;35(4):386-92. [PubMed]
8. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, et al. Risk factors for Osteonecrosis of the jaws: a case-control study from the CONDOR Dental PBRN. J Dent Res. 2011 Apr;90(4):439-44. [PubMed]
9. Hasegawa Y, Kawabe M, Kimura H, Kurita K, Fukuta J, Urade M. Influence of dentures in the initial occurrence site on the prognosis of bisphosphonate-related Osteonecrosis of the jaws: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Sep;114(3):318-24. [PubMed]
10. Otto S, Pautke C, VandenWyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. CancerTreatRev. 2018 Sep;69:177-187. [PubMed]
11. Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol. 2017 Jun 24;S1808-8694(17)30097-6. [PubMed]
12. Wang Q, Liu J, Qi S, Liao X, Liu D, Pan J. Clinical analysis of medication-related osteonecrosis of the jaws: A growing severe complication in China. J Dent Sci. 2018 Sep;13(3):190-197. [PubMed]
13. Matsuda S, Yoshimura H, Sano K. Risk factors and treatments for medication-related Osteonecrosis of the jaw: A 10-year single-institution experience. Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology. J Oral Maxillofac Surg Med Pathol.2018 Jan;30(1):10-16. [Crossref]
14. Klingelhoffer C, Zeman F, Meier J, Reichert TE, Ettl T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related Osteonecrosis of the jaws. J Craniomaxillofac Surg. 2016 Oct;44(10):1694-1699. [PubMed]
15. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic Acid and targeted therapy is active but may induce Osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 2013 Sep;71(9):1532-40.[PubMed]
16. Watters AL, Hansen HJ, Williams T, Chou JF, Riedel E, Halpern J, et al. Intravenous bisphosphonate-related Osteonecrosis of the jaw: long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Feb;115(2):192-200. [PubMed]
17. Lee L-W, Hsiao S-H, Chen L-K. Clinical treatment outcomes for 40 patients with bisphosphonates-related Osteonecrosis of the jaws. J Formos Med Assoc. 2014 Mar;113(3):166-72. [PubMed]
18. Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, et al. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. Biol Pharm Bull. 2015;38(12):1850-5. [PubMed]
19. Rahimi-Nedjat RK, Sagheb K, Pabst A, Olk L. Christian Walter C. Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw. Dent J (Basel). 2016 May 31;4(2):17. [PubMed]
20Oteri G, Campisi G, Panzarella V, Morreale I, Nucera R, Di Fede O, et al. Picone A, Marcianò A. Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients? Biomed Res Int. 2018 May 29;2018:4021952. [PubMed]
21. Higuchi T, Soga Y, Muro M. Replacing zoledronic acid with denosumab is a risk factor for developing Osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):547-551. [PubMed].
Received: 05 December 2019
Published online: 22 January 2021